CVE-2024-12901

Public Exploit
FoxCMS API Endpoint Site.php improper authorization

Description

A vulnerability classified as critical was found in FoxCMS up to 1.2. Affected by this vulnerability is an unknown functionality of the file /app/api/controller/Site.php of the component API Endpoint. The manipulation of the argument password leads to improper authorization. The attack can be launched remotely. The exploit has been disclosed to the public and may be used.

Category

6.9
CVSS
Severity: Medium
CVSS 4.0 •
CVSS 3.1 •
CVSS 2.0 •
EPSS 0.04%
Third-Party Advisory vuldb.com
Affected: n/a FoxCMS
Published at:
Updated at:

References

Link Tags
https://vuldb.com/?id.289171 vdb entry technical description
https://vuldb.com/?ctiid.289171 signature permissions required
https://vuldb.com/?submit.467703 third party advisory
https://note.zhaoj.in/share/8l4RPA2zcxRr broken link exploit

Frequently Asked Questions

What is the severity of CVE-2024-12901?
CVE-2024-12901 has been scored as a medium severity vulnerability.
How to fix CVE-2024-12901?
To fix CVE-2024-12901, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2024-12901 being actively exploited in the wild?
It is possible that CVE-2024-12901 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2024-12901?
CVE-2024-12901 affects n/a FoxCMS.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.